A 30-year-old Portuguese male patient, weight 60 kg, was admitted to the emergency ward with complaints of severe headaches, drowsiness, stiff neck, photophobia, nausea, and unusual high blood pressure (180 mm Hg systolic) for the past 24 hours. The Glasgow Coma Scale on his arrival was evaluated to be 14 with no focal neurological deficit. The patient was previously diagnosed to have a factor XI deficiency (discovered in 1985, because of unusual bleeding after dental extraction and after a cyst removal on the lateral left side of the neck). A brain CT scan showed a subarachnoid hemorrhage without any ventricular abnormality or any intracranial hematoma. Routine blood analysis reported a prolonged aPTT (activated partial thromboplastin time/ Star2 Stago France) of 46 seconds (normal range: 32 ± 8) and a normal prothrombin time. Because of the history of factor XI deficiency, plasmatic level of factor XI coagulant activity was measured and was at 0.08 UI.ml -1 (ie, 8%, normal range: 70%-100%). S ubarachnoid hemorrhage (SAH) resulting from cerebral aneurysm rupture accounts for a high morbidity and mortality rate, 1,2 When SAH is associated with a coagulation disorder, an unexpected and possible increase in hemorrhagic stroke with enlarged intracranial hematoma 3 and other bleeding complications could occur, leading to extreme risk of death.
We report a case of successful clinical management of an aneurysmal SAH in a patient with inherited coagulation factor XI deficiency. No such specific case had been reported. However, a small number of reports concerning spontaneous intracerebral hemorrhage with other inherited bleeding disorders had been published. [4] [5] [6] The authors report a rare case of an acute cerebral aneurysm rupture in a patient with a known factor XI deficiency. Aneurysmal subarachnoid hemorrhage (SAH) accounts for a high mortality and morbidity rate. When SAH is associated with an inherited coagulation disorder such as hemophilia C, an unexpected and possible increase in hemorrhagic stroke and increase in bleeding during surgery and in the postoperative period could lead to an extremely bad outcome. Clinical management consists of rapid correction of the coagulation disorder before undergoing any invasive intracranial procedure. Such an optimal therapeutic strategy must be under the care of a multidisciplinary medical and surgical team. Human factor XI concentrate (Hemoleven, Laboratoire Français du Fractionnement et des Biotechnologies [LFB], Les Ulis, France) was used successfully in this case report. New treatment using recombinant factor VIIa is discussed.
Keywords: factor XI deficiency; inherited bleeding disorder; intracranial hemorrhage; aneurysmal subarachnoid hemorrhage; human factor XI concentrate; recombinant factor VIIa This patient was likely exposed to a bleeding risk with potential increase in the hemorrhagic stroke and possible extension of the SAH leading to immediate neurological risk. This situation imposed an immediate therapeutic strategy defined under the care of a multidisciplinary medical team involving a neurosurgeon, anesthesiologist, hematologist, and radiologist. Human factor concentrate Hemoleven ([HFC], Laboratoire Français du Fractionnement et des Biotechnologies [LFB], Les Ulis, France), was rapidly introduced to replace the deficient factor to at least 0.40 UI ml -1 (ie, 40%) before undergoing any invasive procedure. A 4-vessel cerebral angiography was performed and revealed a ruptured aneurysm on the anterior communicating artery (ACoA) and 2 nonruptured aneurysms, facing each other on the right and left internal carotid artery termination (ICA). The patient was classified "Fisher 2" and graded "WFNS II." On the following day, the neurological state of the patient worsened and the Glasgow Coma Scale fell to 12 with hyperthermia (38.5°C) and clinical evidence of vasospasm. Medical treatment consisted of 3H-therapy (hemodilution, hypervolemia, and controlled hypertension), intravenous nimodipine at the rate of 0.03 mg.Kg -1 H -1 , under invasive monitoring of the arterial blood pressure, associated with administration of HFC at the rate of 30 UI.Kg -1 to maintain the factor XI coagulant activity to a plasmatic level above 0.40 UI.ml -1 . Daily routine coagulation tests and thrombosis markers (platelets count, Fibrinogen, factor V, and fibrin degradation products [FDP]) were measured. Ten days after the hemorrhagic stroke, the clinical status of the patient was stabilized, and neurosurgical clipping of the ACoA aneurysm was performed successfully. The recovery (plasmatic level factor XI coagulant activity) was then at 0.69 UI.ml -1 . In the postoperative period, we continued to administrate lower doses of HFC in the following 72 hours to maintain the factor XI plasmatic coagulant activity over 0.40 UI.ml -1 . No postoperative bleeding and no thrombosis complications were observed. The patient was discharged from hospital after complete recovery. Three months later, the patient was readmitted for the treatment of the remaining aneurysms. Endovascular procedure was decided instead of surgical clipping. The patient was infused preliminarily with HFC (30 UI.kg -1 ) for recovery and half-life determination, and received 15 UI.Kg -1 of HFC 24 hours before and the same dose on the day while starting the endovascular procedure. A 4-vessel angiography showed a partial recanalization of the initially clipped ACoA aneurysm and the 2 nonruptured ICA aneurysms. Under general anesthesia, the aneurysm on the right ICA termination was embolized with 3 coils, and the recanalization of the ACoA was completed with 2 coils. During the endovascular procedure, heparin within the usual protocol was administrated as prevention of thromboembolic events. The left ICA aneurysm was so small that no treatment was necessary. Thrombosis markers were daily measured. No postoperative complication was observed. This patient left the hospital a week later.
Discussion
Factor XI deficiency (incidence: 1/100 000), also called hemophilia C or plasma thromboplastin antecedent deficiency, was first described in 1953 in an American Jewish family by Rosenthal. It represents 7% of all hereditary coagulation factor deficiencies 7-9 and remains a rare and an uncommon cause of spontaneous intracranial bleeding. The inheritance of this deficiency is autosomal, affecting equally males and females. Even if hemophilia C is known to have a high prevalence among Ashkenazi Jews, it has been reported in most racial groups. 10, 11 Unlike hemophilia A or B, 12 factor XI deficiency is known to have unpredictable bleeding tendency after surgery or after any injury. And the severity of the bleeding tendency does not correlate with the plasmatic level of factor XI. This unpredictable bleeding tendency is not fully understood. However, studies have confirmed that 20% to 50% of patients with partial deficiency (levels of 0.20 to 0.60 UI ml -1 of factor XI coagulant activity) experience excessive bleeding and individuals with severe deficiency (levels <0.20 UI ml -1 ) do not suffer from spontaneous bleeding but are at high risk of bleeding after surgery. [13] [14] [15] The incidence of SAH in patients with factor XI deficiency is unknown. Combined with SAH, which is known to have a high re-bleeding risk in the days following the initial subarachnoid hemorrhage peak, 16 perioperative management 17,18 becomes a challenge and imposes an optimal therapeutic strategy, which must be under the care of a multidisciplinary medical and surgical team. Specific therapy is needed prior to any invasive and surgical procedures. Several treatments are available, including factor XI concentrate and fresh frozen plasma (FFP) for major surgery when plasmatic levels of factor XI are less than 10%. Fibrin glue, antifibrinolytic drugs, and desmopressin may be used in minor surgery. 18 And because of life-threatening bleeding situations, development of new hemostatic therapeutics is rapidly growing.
Factor XI concentrate is not commercially available and is not licensed for use in the United States at this time. When factor XI concentrate is not available, the product of choice is FFP. FFP is currently infused intravenously with a loading dose of 15 to 20 ml.Kg -1 , followed by 3 to 6 ml Kg -1 every 12 hours until hemostasis is achieved. Considerable amounts of FFP are needed to maintain the factor XI level. The plasma half-life of factor XI is approximately 80 hours. The disadvantages of FFP include large volume of infusion, potential risk of transmission of infectious viruses, and possible allergic reactions. However, the risk of infection can be avoided by using solvent-detergent plasma or heat-treated concentrate.
In this case report, HFC was used to correct the factor XI deficiency instead of FFP prior to intracranial procedures, because it provides a good source of replacement due to selective delivery of deficient factor, with smaller volume of infusion avoiding fluid overloading. Furthermore, this HFC is a heattreated plasma-derived product and is hence expected not to transmit any virus such as hepatitis or HIV viruses. 19 However, infusion of HFC should be prudent because in some cases thrombosis events 20 have been reported, especially when the infused doses were above 30 UI.Kg -1 . And for this reason, when HFC is used, the infused dose must not exceed 30 UI.Kg -1 , and the target concentration (peak factor XI level) should be below 70% in patients with severe deficiency. Monitoring the thrombosis markers regularly is crucial as well as the plasmatic level of factor XI and half-life time. Recovery was 69%, with a half-life of 46 hours. Good hemostatic efficacy was observed during the neurosurgical clipping, and there was no thromboembolic complication. In the postoperative period, and because of the unpredictable bleeding nature after surgery, infusion of HFC had to be continued within the following 72 hours keeping the plasmatic level of factor XI coagulant activity over 0.40 UI.ml -1 to prevent postoperative hemorrhage. At the same time, clinical management of SAH, following national guidelines, was applied. 21, 22 We renewed the infusion of HFC 3 months later when preparing this patient for endovascular procedures for the remaining intracranial aneurysms. Thromboembolic and ischemic complications are the major source of problems during coil embolization procedures because of associated artery injury and the thrombogenic characteristics of arterial catheters, contrast agents, and implanted devices such as stents and coils. 23 And the infusion of HFC during these procedures can accelerate these complications, even under a combination with prophylaxis treatment using conventional anticoagulation with heparin and antiplatelet therapies. During endovascular aneurysm coiling, the clinical management must focus on a strict correction of the coagulation abnormalities under the control of thrombosis markers and monitoring of coagulation tests for adequate anticoagulation. In this case report, we experienced good results using human factor XI concentrate (LFB, Les Ulis, France).
New treatments focus on the interest of recombinant factor VIIa (rFcVIIa) in severe bleeding and intracranial hemorrhage. 24, 25 Originally rFcVIIa was developed for treatment of bleeding in hemophilia for patients having inhibitors and auto-antibodies against factor VIII or IX. The use of rFcVIIa in major surgery has been found to induce hemostasis. 26 Administration of pharmacologic doses of rFcVIIa enhances thrombin generation on activated platelets. Roberts et al 27 indicate that factor XI can be activated by thrombin in the absence of factor XII and that the function of factor XI is simply to enhance the activation of factor IX to factor IXa, resulting in enhanced thrombin generation on the platelet surface. Recent data in the literature suggested that for major surgery, rFcVIIa may improve hemostasis in situations involving impaired thrombin generation by giving a bolus dose of 90 to 110 µg.Kg -1 every second hour for at least the first 24 hours. 28 Such treatment is quite promising, but further studies including randomized prospective trials are needed.
